Oncology News and Research

RSS
Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

i3 completes acquisition of ChinaGate

i3 completes acquisition of ChinaGate

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

University of Arkansas to host the 2010 Advances in Breast Cancer Research workshop

University of Arkansas to host the 2010 Advances in Breast Cancer Research workshop

Researchers identify cancer gene that could help fight paediatric glioma

Researchers identify cancer gene that could help fight paediatric glioma

Roche Diagnostics, ACC collaborate to develop biomarkers clinical resource Web portal

Roche Diagnostics, ACC collaborate to develop biomarkers clinical resource Web portal

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

Senesco Technologies third-quarter net loss increases to $5.28M

Senesco Technologies third-quarter net loss increases to $5.28M

Varian Medical Systems launches fully-integrated ProBeam proton therapy system at 2010 PT-COG

Varian Medical Systems launches fully-integrated ProBeam proton therapy system at 2010 PT-COG

TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M

TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Neoprobe gamma radiation detection systems featured in RSL peer review in American Journal of Surgery

Neoprobe gamma radiation detection systems featured in RSL peer review in American Journal of Surgery

New DVS radiation measurement device for prostate cancer treatment

New DVS radiation measurement device for prostate cancer treatment

Cancer Research UK launches new cancer centre in Leeds

Cancer Research UK launches new cancer centre in Leeds

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.